Hos patienter med multiple myelomer kan risikoen for nedsat nyrefunktion øges når intravenøse bisfosfonater anvendes i kombination med thalidomid.
In multiple myeloma patients, the risk of renal dysfunction may be increased when intravenous bisphosphonates are used in combination with thalidomide.